
© 2025 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
41,890 | 41,970 | 19.05. | |
41,775 | 42,110 | 07:03 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mo | Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects? | ||
Mo | EC approves BMS' perioperative Opdivo and chemo for NSCLC | ||
Fr | Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb | ||
Fr | Bristol Myers gets EU nod for Opdivo combo in lung cancer treatment | ||
Fr | Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression =1% | Approval based on results from the CheckMate-77T trial which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant... ► Artikel lesen |